ABSTRACT:
Disorders in the regulation of the alternate complement pathway often result in complement-mediated damage to the microvascular endothelium and can be associated with both glomerulonephritis and atypical haemolytic uraemic syndrome. Inherited defects in complement regulatory genes or autoantibodies against complement regulatory proteins are predictive of the severity of the disease and the risk of recurrence post kidney transplantation. Heterozygous mutations in CD46, which codes for a transmembrane cofactor glycoprotein membrane cofactor protein, usually have a lower incidence of endstage kidney disease and decreased risk of recurrent disease post transplant, as wild-type membrane cofactor protein is present in the transplanted kidney. However, some patients with CD46 mutations have a second variant in other complement regulatory genes increasing the severity of disease. The following case report illustrates the course of a young adult patient with end-stage kidney disease initially ascribed to seronegative systemic lupus erythematosus, who presented with biopsy-proven thrombotic microangiopathy following kidney transplantation. It highlights the complexity associated with disorders of complement regulationand theneedfora high index ofsuspicionand genetic testing in patients who present with thrombotic microangiopathy post-transplant.
Over-exuberant activation of the alternative complement pathway is usually prevented by a system of regulatory proteins. Genetic or acquired dysfunction of this regulatory system is now recognized to play a critical role in the pathophysiology of several kidney diseases including atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy and CFHR5-related nephropathy.
1,2 The most common genetic cause for aHUS is mutation of complement factor H (CFH) leading to CFH dysfunction, but mutation of several other genes is also associated with complement-related diseases, including CD46 that encodes membrane cofactor protein (MCP). 3, 4 A small but significant number of patients with CD46 mutations also have a second mutation in another complement regulatory gene resulting in a more severe phenotype. 3, 4 This case describes a patient with end-stage kidney disease (ESKD) initially ascribed to seronegative lupus nephritis who experienced recurrent aHUS after kidney transplantation due to mutation of CD46 mutation on a background of SMARCAL1-mediated inherited kidney disease.
CASE REPORT
In 2006, a 15-year-old girl presented for investigation of nephrotic-range proteinuria of 4.4 g/day and persistent microscopic haematuria. She reported no symptoms, specifically no gastrointestinal or rheumatological manifestations, and had no prior medical or surgical co-morbidities. There was no family history of any illnesses at that time. On examination, she was hypertensive at 190/80 mmHg. She was of short stature (147 cm, 1st centile), but there were no other abnormalities.
Investigations at this time revealed a normal full blood count, a serum creatinine concentration of 60 μmol/L, a serum albumin concentration of 37 g/L, negative hepatitis B and C serology, negative antinuclear antibody, negative double stranded DNA antibody, negative antibody to extractible nuclear antigens, normal ratio serum free light chains, negative cryoglobulin screen, and a negative serum protein electrophoresis.
Complement C3 and C4 levels were both normal at 1.26 (0.70-1.60) and 0.20 g/L (0.10-0.30), respectively.
A kidney biopsy was reported as consistent with World Health Organization class IV lupus nephritis with endocapillary proliferation, segmental wire loops and hyaline thrombi. Immunofluoresence showed granular deposits of IgG (3-4+), IgA (1-2+), IgM (2+), C3 (3+) and C1q (1-2+) in all glomeruli. The C3 was marked and staining involved mesangium and segmental capillary walls. There were no features of thrombotic microangiopathy (TMA).
Initial management consisted of irbesartan and immunosuppressive treatment consisted of mycophenolate mofetil and prednisolone.
She was unresponsive to immunosuppressive therapy and progressed to ESKD in 2011, when she commenced renal replacement therapy and proceeded to kidney transplantation work-up. At this time, the patient's younger brother developed proteinuria, and his kidney biopsy similarly demonstrated diffuse podocyte foot-process effacement but no immune complex deposition or features of TMA. Both parents reported no family history of kidney disease.
In March 2013, the patient underwent deceased donor kidney transplantation. Her transplant was a three human leukocyte antigen mismatch and was unsensitized, and the cytomegalovirus (CMV) status of the donor was positive, and the recipient was negative. Induction immunosuppression consisted of basiliximab, tacrolimus, mycophenolate mofetil and prednisolone. Prophylactic valgancyclovir was commenced. A post-perfusion implantation kidney biopsy showed acute tubular necrosis.
The patient's serum creatinine concentration fell from a pre-operative level of 585 to 120 μmol/L 21 days following kidney transplantation. At 35 days after kidney transplantation, the serum creatinine concentration rose abruptly to 180 μmol/L. Her trough serum tacrolimus level was in the therapeutic range at 8.1 ng/L, and qualitative BK PCR virus was negative. A full blood count revealed a stable haemoglobin level (117 g/L) and platelet count (236 × 10 9 /L). Examination of the peripheral blood film did not demonstrate any schistocytes. A transplant kidney biopsy showed features of TMA with severe mesangiolysis, double contours in capillary loops, hyaline deposits in capillaries and red cell fragments; there was no evidence of cellular or antibody-mediated allograft rejection (Fig. 1a,b) . Review of past haematology results revealed episodes of mild anaemia and thrombocytopenia with elevations in serum lactate dehydrogenase prior to presentation with kidney disease that had not been investigated.
A provisional diagnosis of aHUS was made. Plasmapheresis was commenced, and target tacrolimus levels were reduced. After 12 days of treatment, there was a significant improvement in kidney function, and plasmapheresis was slowly weaned. A repeat of kidney biopsy, 56 days after kidney transplant, showed resolving TMA, with a single arteriolar thrombus present. Nine weeks later, the serum creatinine concentration rose again to 170 μmol/L, in association with a fall in haemoglobin level to 74 g/L and platelet count to 17 × 10 9 /L. There were no schistocytes observed on peripheral blood film, and the haptoglobin was normal, although the serum lactate dehydrogenase rose to 691 U/L. A repeat kidney biopsy showed active TMA. Plasmapheresis was reinstituted, and belatacept was substituted for tacrolimus in case the calcineurin inhibitor was exacerbating the TMA, leading to gradual improvement in haematological parameters and kidney function (Fig. 2) . At 34 weeks post transplant, the patient became rapidly unwell and died within 24 hours of presentation to hospital from respiratory failure due to CMV infection. Subsequent genetic testing using a renal gene panel approach identified that she had a heterozygous CD46 mutation (c.286 + 2 T > G) as well as compound heterozygous SMARCAL1 mutations (c.1975C > T and c.2193del).
DISCUSSION
Thrombotic microangiopathy after kidney transplantation may result from a number of causes, and a concerted effort to distinguish the cause of the TMA should be undertaken. Importantly, the initial cause of the ESKD should be carefully reviewed; as in this case, the original diagnosis of seronegative lupus nephritis was likely incorrect. In addition, the finding of prior episodes consistent with microangiopathic haemolytic anaemia may have assisted with a diagnosis of a complement disorder and raised the awareness of the risk of post-transplant recurrence. The exclusion of antibody mediated rejection is paramount, because there is overlap in the histological features.
An unique aspect of this case is the combined CD46 and SMARCAL1 mutations, 5 which predisposes patients to aHUS and inherited kidney disease, respectively. Although CD46 mutations are usually associated with more favourable posttransplant outcomes, this patient's severe disease may have been exacerbated by SMARCAL1-mediated immune compromise. aHUS patients with CD46 mutations have been described to have a lower risk of post-transplant aHUS recurrence, because the gene product (MCP) is a membrane-bound protein, and therefore, wild-type MCP is expressed by the allograft. 4, 5 However, a recent large study of aHUS patients revealed unexpected recurrence of disease after transplantation in some with CD46 mutations, 5 which may be partially explained by the fact that a proportion of patients with CD46 mutations also had additional mutations in genes encoding circulating complement factors. 6 In addition, CD46 is also abundantly expressed on both platelets and leucocytes and which may contribute to the ongoing complement dysregulation. The patient described in this report additionally had compound heterozygous SMARCAL1 mutations. SMARCAL1 encodes an ATP-driven annealing helicase whose enzymatic activity plays essential roles in DNA-nucleosome restructuring and chromatin remodelling during gene regulation as well as in DNA replication and repair (11, 12) . Loss of function mutations in SMARCAL1 in patients causes Schimke immunoosseous dysplasia, for which ESKD including podocyte dysfunction is a leading primary complication. Other clinical features of Schimke immuno-osseous dysplasia include spondylo-epiphyseal dysplasia, short stature, T cell deficiency/dysfunction and hyperpigmented macules. The T cell deficiency in conjunction with systemic immunosuppression likely contributed to this patient's catastrophic CMV infection that led to her death. Additionally, these genetic findings have significant implications for the overall management of her brother currently and in the future. Another important insight gained from this case was the improvement in the patient's serum creatinine upon withdrawal of tacrolimus and the introduction of belatacept as part of her immunosuppressive regimen. Calcineurin inhibitors are well described as potential triggers for post-transplant HUS. Injury to allograft endothelium may occur as a result of dosedependent vasoconstriction, endothelial cell toxicity and promotion of a prothrombotic state. Additionally, mammalian target of rapamycin inhibitors alone and in combination with calcineurin inhibitors have also been associated with post transplant TMA. In this case, minimization and eventual withdrawal of tacrolimus was associated with improvement in the severity of TMA. Belatacept is a fusion protein of the extracellular domain of cytotoxic T-lymphocyte antigen-4 with the Fc portion of IgG and has been used as an alternate immunosuppressive agent in patients with post-transplant aHUS. This agent binds to CD80 and CD86 receptors on the alternative complement pathway; therefore, blocking the required CD28-mediated interaction between antigen presenting cells and T cells needed to activate T lymphocytes. 5 However, belatacept, which was substituted as an immunosuppressant for tacrolimus, may have exacerbated T cell dysfunction due to the background SMARCAL1 mediated inherited disease (14,15).
CONCLUSION
In summary, this case illustrates that aHUS can occur following kidney transplantation and should be considered as a cause of TMA, even when it was not identified as the original cause of ESKD. Furthermore, complement regulatory gene mutations are found in many cases of aHUS and have a bearing on the risk Additionally, a positive family history should prompt consideration of an underlying inherited kidney disease. Thus, this case demonstrates learning outcomes for both experienced and training nephrologist with regard to diagnostic and management issues underpinning complement disorders such as aHUS.
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